newsfilter
← Latest News
GlobeNewswire·

iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates

– Initiated a randomized Phase 2 trial evaluating anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and GSK's anti-PD-1 Jemperli (dostarlimab) in first line, metastatic non-small cell lung cancer – Phase 2 trials with